Because of the functional significance of piR-1742 in the onset and progression of RCC, targeting the piR-1742/USP8/MUC12 axis with selective nanomaterial carriers may constitute an interesting therapeutic option for the treatment of RCC (Fig. 8j). This evidence concerns the gene MUC12 and renal cell adenocarcinoma.